Dogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Dogwood Therapeutics Inc DWTX.OQ reported a quarterly adjusted loss of $1.99​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.25. The mean expectation of three analysts for the quarter was for a loss of $1.90 per share. Wall Street expected results to range from $-3.19 to -51 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Dogwood Therapeutics Inc's reported EPS for the quarter was a loss of $1.99​.

• The company reported a quarterly loss of $3.81 million.

• Dogwood Therapeutics Inc shares had risen by 1.7% this quarter and gained 94.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Dogwood Therapeutics Inc is $11.00, about 55.9% above its last closing price of $4.85

This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)